GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week ...
Side effects of GLP-1 drugs commonly include nausea, vomiting, and delayed gastric emptying that can lead to heartburn and ...
NSCLC showed the largest reduction in metastatic progression with GLP-1RAs versus gliptins (HR 0.50), with significant ...
Nephrologists are initiating SGLT2 inhibitors earlier in the chronic kidney disease (CKD) treatment journey and continuing them well below labeled eGFR thresholds. At the same time, real-world uptake ...
Among patients with obesity, GLP-1 RAs were associated with a lower hazard of all-cause mortality and recurrence-free survival over a 10-year follow-up period. (HealthDay News) â Glucagon-like peptide ...
Primary care practitioners serve a critical role in optimizing clinical outcomes for adults with T2DM by evaluating underlying mechanisms, treatment efficacy, medication safety profiles, and ...
A recent study found that GLP-1 medications like Ozempic and Wegovy may help improve breast cancer survival rates among women ...
âStudy findings highlight the need for improved recommendations of guideline-directed therapies and support the consideration of dual therapy in appropriately selected high-risk patients. In a study ...
Patients with type 2 diabetes and inflammatory arthritis who received GLP-1 RAs had lower rates of hypoglycemia, serious infections, and acute kidney injury vs those receiving SGLT2 inhibitors.
Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors were linked to lower risks for CKD and AKI but greater risks for albuminuria vs. GLP-1s. Risk ...
A large cohort study found three popular GLP-1-based diabetes drugs -- semaglutide, dulaglutide, and tirzepatide -- carry similar risks for serious adverse GI events, with a rate of about 12 per 1,000 ...
HealthDay on MSN
GLP-1 receptor agonists tied to better outcomes in certain patients with breast cancer
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with better outcomes among patients with breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results